Also listed under Inflammatory Bowel Diseases
ClinicalTrials.gov term: Colitis, Ulcerative
Ulcerative Colitis clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-10
What changed in the last 30 days
59 trials changed in the last 30 days: 3 stopped, 21 with notable changes, 35 with minor changes only.
- Notable: Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative Colitis Recruitment opened
- Minor: Microbiome-targeted Diet Therapy in Ulcerative Colitis Start date moved earlier from Nov 9, 2026 to Nov 4, 2026
-
Minor: 7 trials marked Unknown by the registry's verification sweep Changed
- Minor: QUANTUM · Quest to Analyze One Thousand Humans Meditating Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Enrolling by Invitation
- Minor: Zuoqing SAN in Treating Ulcerative Colitis Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
- Minor: TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
- Minor: CSRRUC · Critical State of "Remission-Recurrence" of Ulcerative Colitis Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Minor: ProZ-UC · ProLife 10 FORTE on Gut Microbiota Composition in UC Patients Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Minor: CONF-UC · Prognostic Value of Confocal Endomicroscopy in Ulcerative Colitis: the CONF-UC Study Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
- Minor: Acupuncture for Symptom Relief · Mild to Moderate Ulcerative Colitis Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
- Notable: MOVE-IT · MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease Enrolling by invitation only
- Notable: IB DYSPLASIA · Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study Recruitment opened
- Minor: EFFECT-1LAT · Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population Trial completed
- Notable: Sub Study to Investigate the Safety and Tolerability of Aletekitug · Moderate To Severe Ulcerative Colitis Recruitment opened
- Minor: AMETRINE-PEDS · Afimkibart (RO7790121) · Moderately to Severely Active Ulcerative Colitis Trial sites expanded: 26 → 29 locations
- Notable: GRACE · National GMA Post-market Clinical Follow-up Study Primary and study completion pushed from Jun 30, 2026 to Jun 30, 2027
- Minor: Social Determinants of Health, Medication Use, and Quality of Life in Inflammatory Bowel Disease Trial completed
- Notable: Tulisokibart · Crohn's Disease or Ulcerative Colitis (MK-7240-011) Primary endpoint(s) modified
- Minor: ICONIC-UC · Protocol of Icotrokinra Therapy in Adult and Adolescent · Moderately to Severely Active Ulcerative Colitis Enrollment closed, study ongoing
- Minor: DUET ENCORE-UC · JNJ-78934804 · Moderately to Severely Active Ulcerative Colitis Trial sites expanded: 279 → 318 locations
- Minor: SKYLINE-LTE · Long-acting Antibodies Alone and in Combinations for IBD Trial sites expanded: 91 → 98 locations
- Minor: GALILEO · Real-World Study of Guselkumab Persistence and Effectiveness · Crohn's Disease or Ulcerative Colitis Start date pushed from Oct 30, 2026 to Nov 15, 2026
- Minor: GusTaCon · Continued Use of Guselkumab · Crohn's Disease and Ulcerative Colitis in Real World Setting Start date pushed from Oct 30, 2026 to Nov 12, 2026
- Notable: Aquamin® · Ulcerative Colitis J-Pouch-associate Intestinal Inflammation Primary endpoint(s) modified
- Minor: LEGACY · Registry of Humira® (Adalimumab) · Moderately to Severely Active Ulcerative Colitis (UC) Trial completed
- Minor: COLOR UC · Brivekimig · Ulcerative Colitis Trial sites expanded: 66 → 69 locations
- Notable: ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool Enrollment increased: 220 → 1000 participants
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-11-04 | NCT07916493 Effects of Different Physical Activity Strategies on Disease Activity of IBD Patients | Szeged University new | |
| 2026-11-03 | NCT07913347 Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT… | Metagen Therapeutics, Inc. new | Phase 1/2 |
| 2026-10-28 | NCT07900945 Study of Single and Multiple Ascending Doses of CM551 in Healthy Participants | Keymed Biosciences Co.Ltd new | Phase 1 |
| 2026-10-09 | NCT07869225 A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and… | Equillium new | Phase 1 |
| 2026-10-05 | NCT07857447 The Effects of a Modified Mediterranean Diet on Ulcerative Colitis Patients | University Hospital Sestre Milosrdnice new | |
| 2026-09-30 | NCT07848737 A Real-World Study of Guselkumab Persistence and Effectiveness in Participants With… | Janssen-Cilag, S.A. new | |
| 2026-09-22 | NCT07834515 Phase 1b Clinical Study in Patients With Active Ulcerative Colitis | Thetis Pharmaceuticals LLC new | Phase 1 |
| 2026-09-18 | NCT07828886 Immune Aging and Advanced Therapy Outcomes in Older Adults With IBD | First Affiliated Hospital, Sun Yat-Sen University new | |
| 2026-09-17 | NCT07824726 Ex Vivo Comparison Of Combination Versus Single Therapeutic Pathway Inhibition In Human… | PhoenixLAB srls new | |
| 2026-09-15 | NCT07819799 Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With… | Attovia Therapeutics Inc new | Phase 1 |
Active trials by phase
| Early Phase 1 | 8 | |
| Phase 1 | 28 | |
| Phase 1/2 | 11 | |
| Phase 2 | 72 | |
| Phase 2/3 | 7 | |
| Phase 3 | 39 | |
| Phase 4 | 38 |
Not charted: 290 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
AbbVie (13) · Assiut University (10) · Janssen Research & Development, LLC (10) · Takeda (10) · Eli Lilly and Company (7) · Pfizer (7) · Assistance Publique - Hôpitaux de Paris (6) · Sanofi (6) · Second Affiliated Hospital, Zhejiang University, School of Medicine (6) · Tanta University (6)
Get alerts when Ulcerative Colitis trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.